The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
Authors:
Open Access
- 12 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 16 (1) , 1-12
Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic inflammatory respiratory diseases, which impose a substantial burden on healthcare systems and society. Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), often administered using dry powder inhalers (DPIs), are frequently prescribed to control persistent asthma and COPD. Use of DPIs has been associated with poor inhalation technique, which can lead to increased healthcare resource use and costs. A model was developed to estimate the healthcare resource use and costs associated with asthma and COPD management in people using commonly prescribed DPIs (budesonide + formoterol Turbuhaler® or fluticasone + salmeterol Accuhaler®) over 1 year in Spain, Sweden and the United Kingdom (UK). The model considered direct costs (inhaler acquisition costs and scheduled and unscheduled healthcare costs), indirect costs (productive days lost), and estimated the contribution of poor inhalation technique to the burden of illness. The direct cost burden of managing asthma and COPD for people using budesonide + formoterol Turbuhaler® or fluticasone + salmeterol Accuhaler® in 2015 was estimated at €813 million, €560 million, and €774 million for Spain, Sweden and the UK, respectively. Poor inhalation technique comprised 2.2–7.7 % of direct costs, totalling €105 million across the three countries. When lost productivity costs were included, total expenditure increased to €1.4 billion, €1.7 billion and €3.3 billion in Spain, Sweden and the UK, respectively, with €782 million attributable to poor inhalation technique across the three countries. Sensitivity analyses showed that the model results were most sensitive to changes in the proportion of patients prescribed ICS and LABA FDCs, and least sensitive to differences in the number of antimicrobials and oral corticosteroids prescribed. The cost of managing asthma and COPD using commonly prescribed DPIs is considerable. A substantial, and avoidable, contributor to this burden is poor inhalation technique. Measures that can improve inhalation technique with current DPIs, such as easier-to-use inhalers or better patient training, could offer benefits to patients and healthcare providers through improving disease outcomes and lowering costs.Keywords
This publication has 47 references indexed in Scilit:
- Is the BTS/SIGN guideline confusing? A retrospective database analysis of asthma therapyPrimary Care Respiratory Journal, 2013
- Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort studyBMC Pulmonary Medicine, 2013
- ‘The blue one takes a battering’ why do young adults with asthma overuse bronchodilator inhalers? A qualitative study: Table 1BMJ Open, 2013
- Factors associated with health-related quality of life in adults with asthma. A cross-sectional studyMultidisciplinary Respiratory Medicine, 2012
- Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 yearsEuropean Respiratory Review, 2012
- Validity of two common asthma-specific quality of life questionnaires: Juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaireHealth and Quality of Life Outcomes, 2012
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- What the pulmonary specialist should know about the new inhalation therapiesEuropean Respiratory Journal, 2011
- Economic burden of asthma: a systematic reviewBMC Pulmonary Medicine, 2009
- The DiskusTM: a review of its position among dry powder inhaler devicesInternational Journal Of Clinical Practice, 2007